ING Groep NV grew its stake in shares of Gilead Sciences (NASDAQ:GILD) by 1,906.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 86,310 shares of the biopharmaceutical company’s stock after buying an additional 82,008 shares during the period. ING Groep NV’s holdings in Gilead Sciences were worth $6,507,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of the business. Macquarie Group Ltd. raised its position in shares of Gilead Sciences by 26.6% during the third quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock worth $38,836,000 after purchasing an additional 100,741 shares during the period. Parnassus Investments CA raised its position in shares of Gilead Sciences by 2.5% during the fourth quarter. Parnassus Investments CA now owns 19,159,748 shares of the biopharmaceutical company’s stock worth $1,372,604,000 after purchasing an additional 464,609 shares during the period. Schwab Charles Investment Management Inc. raised its position in shares of Gilead Sciences by 5.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 4,959,388 shares of the biopharmaceutical company’s stock worth $401,810,000 after purchasing an additional 252,556 shares during the period. Hyman Charles D raised its position in shares of Gilead Sciences by 35.9% during the fourth quarter. Hyman Charles D now owns 4,164 shares of the biopharmaceutical company’s stock worth $298,000 after purchasing an additional 1,100 shares during the period. Finally, Sterling Capital Management LLC raised its position in shares of Gilead Sciences by 4.8% during the third quarter. Sterling Capital Management LLC now owns 1,219,771 shares of the biopharmaceutical company’s stock worth $98,826,000 after purchasing an additional 56,020 shares during the period. Hedge funds and other institutional investors own 78.16% of the company’s stock.
Get Gilead Sciences alerts:
Gilead Sciences opened at $68.02 on Friday, Marketbeat reports. The company has a quick ratio of 2.75, a current ratio of 2.84 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $87.90 billion, a price-to-earnings ratio of 7.95, a P/E/G ratio of -5.88 and a beta of 1.19. Gilead Sciences has a twelve month low of $63.76 and a twelve month high of $89.54.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.67 by ($0.19). The company had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.40 billion. Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The firm’s revenue for the quarter was down 21.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.23 earnings per share. research analysts predict that Gilead Sciences will post 5.75 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be paid a $0.57 dividend. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $2.28 dividend on an annualized basis and a yield of 3.35%. Gilead Sciences’s dividend payout ratio is 26.64%.
In other news, EVP Gregg H. Alton sold 14,435 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $81.54, for a total transaction of $1,177,029.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director John Francis Cogan sold 5,836 shares of Gilead Sciences stock in a transaction that occurred on Friday, May 4th. The stock was sold at an average price of $65.09, for a total value of $379,865.24. Following the transaction, the director now owns 58,455 shares of the company’s stock, valued at $3,804,835.95. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 241,102 shares of company stock valued at $18,237,884. Corporate insiders own 1.30% of the company’s stock.
A number of research firms have recently commented on GILD. Zacks Investment Research lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, May 7th. BidaskClub lowered Gilead Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, May 4th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 2nd. Morgan Stanley dropped their target price on Gilead Sciences from $85.00 to $81.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 2nd. Finally, Barclays dropped their target price on Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $88.14.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
